Charles River Laboratories stock saw a 7% return over the past year, but how does it truly measure up against peers scaling in an AI-driven, evolving CRO market facing cost pressures and regulatory shifts? A closer look reveals negative LTM revenue growth and a challenging negative P/E, despite respectable operating and free cash flow margins. CRL’s 7.2% stock gain is modest, with its -97.8 PE reflecting investor concern over recent losses and goodwill impairment. Here’s how Charles River Laboratories International stacks up across size, valuation, and profitability versus key peers. Our wealth management partner builds these robust portfolios to capture growth, while leveraging the Trefis High Quality Portfolio for superior stock selection.

Source: International New York Times February 12, 2026 14:35 UTC